Pediatric tumor lysis syndrome

Journal of Pharmacy Practice

Volumn 17, Issue 6, 2004, Pages 447-454

  Bickert, Betsy ^a   Reilly, Anne ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Allopurinol; Children; Rasburicase; Tumor lysis syndrome

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; ALPHA INTERFERON; ALUMINUM HYDROXIDE; AMOXICILLIN; AMPICILLIN; AMSACRINE; ANTINEOPLASTIC AGENT; CISPLATIN; CLADRIBINE; CORTICOSTEROID; CYCLOSPORIN; CYTARABINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GLUCONATE CALCIUM; HEPARIN; INSULIN; IRINOTECAN; METHOTREXATE; PACLITAXEL; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; RASBURICASE; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; SEVELAMER; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHILD; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DISEASE EXACERBATION; DRUG COST; DRUG HYPERSENSITIVITY; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; HYDRATION; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPOCALCEMIA; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; METHEMOGLOBINEMIA; NAUSEA; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RASH; REVIEW; RISK FACTOR; TUMOR LYSIS SYNDROME; VOMITING;

EID: 10844295866     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190004272552     Document Type: Review

References (37)

1. Jeha S. Tumor lysis syndrome. Semin Hematol. 2001;38(4 suppl 10):4-8.
2. Schifter T, Cohen A, Lewinski UH. Severe tumor lysis syndrome following splenic irradiation. Am J Hematol. 1999;60:75-76.
3. Lobe TE, Karkera MS, Custer MD, et al. Fatal refractory hyperkalemia due to tumor lysis during primary resection for hepatoblastoma. J Pediatr Surg. 1990;25:249-250.
4. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors: a case report and review of the literature. Cancer Chemother Pharmacol. 2003;51:187-192.
5. Annemans L, Moeremans K, Lamotte M. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer. 2003;11:249-257.
6. Navolanic PM, Fui C-H, Larson RA, et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome-a meeting report, Dallas, Texas, January 2002. Leukemia. 2003;17:499-514.
7. Van Der Klooster JM, Van Der Wiel HE, Van Saase JLCM, et al. Asystole during combination chemotherapy for non-Hodgkin's lymphoma: the acute tumor lysis syndrome. Neth J Med. 2000;56:147-152.
8. Altman A. Acute tumor lysis syndrome. Semin Oncol. 2001; 28(2 suppl 5):3-8.
9. Dunlay RW, Camp MA, Allon M, et al. Calcitriol in prolonged hypocalcemia due to tumor lysis syndrome. Ann Intern Med. 1989;110:162-164.
10. Boles JM, Dutel JL, Briere J. Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of acute lymphoblastic leukemia. Cancer. 1984;53:2425-2429.
11. Monballyu J, Zachee J, Verberckmoe SR, et al. Transient acute renal failure due to tumor lysis induced severe phosphate load in a patient with Burkitt lymphoma. Clin Nephrol. 1984;22:47-51.
12. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9:206-212.
13. Ablin A, Stephens BG, Hirata T, et al. Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Metabolism. 1972;21:771-778.
14. Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones: a rare complication of allopurinol therapy. N Engl J Med. 1969;280:426-427.
15. Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med. 1980;68:486-491.
16. Stapleton FB, Strother DR, Roy S, et al. Acute renal failure at the onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics. 1988;82:863-869.
17. Haas M, Ohler L, Watzke H, et al. The spectrum of acute renal failure in tumour lysis syndrome. Nephrol Dial Transplant. 1999;14:776-779.
18. Tsokos GC, Ballow JE, Spiegel RJ, et al. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine. 1981;60:218-229.
19. Hande KR, Hixson CV, Chabner BA. Post chemotherapy purine excretion in patients receiving allopurinol. Cancer Res. 1981;41:2273-2279.
20. Ten Harkel ADJ, Kist-Van Holther JE, Vanweel M, et al. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol. 1998;31:27-28.
21. Band PR, Silverberg DS, Henderson JF, et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med. 1970;283:354-357.
22. Krakoff IH, Meyer RL. Prevention of hyperuricemia in leukemia and lymphoma: use allopurinol, a xanthine oxidase inhibitor. JAMA. 1965;193:89-94.
23. DeConti RC, Calabresi P. Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease. N Engl J Med. 1966;274:481-486.
24. Muggia FM, Ball TJ, Ultmann JE. Allopurinol in the treatment of neoplastic disease complicated by hyperuricemia. Arch Intern Med. 1967;120:12-18.
25. Krakoff H, Murphy ML. Hyperuricemia in neoplastic disease in children: prevention with allopurinol, a xanthine oxidase inhibitor. Pediatrics. 1968;41:52-56.
26. Smalley RV, Guaspari A, Haase-Statz S, et al. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol. 2000;18:1758-1763.
27. Ducros J, Saingra S, Rampal M, et al. Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient. Clin Nephrol. 1991;35:89-90.
28. Pui C-H, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997;11:1813-1816.
29. Pui C-H, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001;19:697-704.
30. Pui C-H, Jeha S, Irwin D, et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia. 2001;15:1505-1509.
31. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998-3003.
32. Pichette V, Leblane M, Bonnandeux A, et al. High dialysate flow rate in continuous arteriovenous hemodialysis: a new approach for the treatment of acute renal failure and tumor lysis syndrome. Am J Kidney Dis. 1994;23:591-596.
33. Heney D, Essex-Cater A, Brocklebank JT, et al. Continuous arteriovenous haemofiltration in the treatment of tumour lysis syndrome. Pediatr Nephrol. 1990;4:245-247.
34. Saccente SL, Kohaut EC, Berkow RL. Prevention of tumor lysis syndrome using continuous veno-venons hemofiltration. Pediatr Nephrol. 1995;9:569-573.
35. Jaing T-H, Hsueh C, Tain Y-L, et al. Tumor lysis syndrome in an infant with langerhans cell histiocytosis successfully treated using continuous arteriovenous hemofiltration. J Pediatr Hematol Oncol. 2001;23:142-144.
36. Sakarcan A, Quigley R. Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol. 1994;8:351-353.
37. Cardinal Health. Medispan. Available at: www.cardinal.com. Accessed October 12, 2004.